A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Latest Information Update: 16 Jan 2020
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 23 Jun 2018 Data will be presented at the American Diabetes Association's (ADA) 78thScientific Sessions 2018, according to an Eli Lilly and Co. media release.
- 23 Jun 2018 Primary endpoint (Change from Baseline in Hemoglobin A1c (HbA1c)) has been met, according to an Eli Lilly and Co. media release.